Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Accured Expenses (2016 - 2025)

Sangamo Therapeutics has reported Change in Accured Expenses over the past 16 years, most recently at $572000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 84.47% year-over-year to $572000.0; the TTM value through Dec 2025 reached $3.1 million, down 46.84%, while the annual FY2025 figure was $3.1 million, 46.84% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $572000.0 at Sangamo Therapeutics, down from $1.7 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $14.6 million in Q4 2022 and troughed at -$7.6 million in Q1 2021.
  • A 5-year average of $1.4 million and a median of $963500.0 in 2025 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: crashed 2291.59% in 2021 and later soared 347.99% in 2024.
  • Year by year, Change in Accured Expenses stood at $5.1 million in 2021, then surged by 187.32% to $14.6 million in 2022, then decreased by 25.83% to $10.8 million in 2023, then plummeted by 65.93% to $3.7 million in 2024, then crashed by 84.47% to $572000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for SGMO at $572000.0 in Q4 2025, $1.7 million in Q3 2025, and $1.4 million in Q2 2025.